Pharmaxis Water For Injection Plant, NSW
The Client
Pharmaxis
Pharmaxis is a specialty pharmaceutical company involved in the research, development and commercialisation of new therapies for undertreated respiratory diseases.
They are focused on developing therapeutic advances for respiratory and immune diseases to patients throughout the world. Founded in 1998, Pharmaxis was listed on the Australian Stock Exchange in 2003 with its head office & manufacturing facilities located in Sydney.
The Client's Needs
Pharmaxis required a water treatment plant to produce Water For Injection (WFI) quality water for the manufacture and packaging of inhalants for supply to the European market. Water For Injection is a very high quality water required for the pharmaceutical industry to meet microbial quality requirements.
Veolia's Solution
Veolia Water Technologies was awarded the contract for the supply of water treatment plant equipment, including pre-treatment to remove suspended solids and chlorine and Distiller, for Pharmaxis’ WF system.
This water treatment plant treats drinking water for the manufacture and packaging of inhalants for supply to the European market. It produces 750 l/hr of water from the pre-treatment plant and 560 l/hr from distillation using the Polaris Electric Vapour Compression Distillation.
The plant combines multimedia filtration, activated carbon, reverse osmosis and continuous deionisation.
The reverse osmosis and continuous deionisation units expand the current production rate of 750 l/hr to 1000 l/hr without any increase to the current footprint.